Independent Equity Research & Structured Analysis, VASRO GmbH

VASRO GmbH

Independent Equity Research & Structured Analysis

VASRO Equity Research Reports provide independent, structured analysis on listed companies, with a focus on public small- and mid-cap issuers, under-covered companies, and cross-border equity stories. Reports typically include company positioning, sector context, financial and strategic analysis, key investor-relevant developments, methodology, and disclosure documentation. Coverage is maintained through recurring and event-driven updates. there are 2 types of ERs, deep-dive rated equity research and non-rated equity research.

Equity Bottom-Up

Saudi Arabian Oil Co., doing business as Saudi Aramco, operates as an oil exploration company. The Company focuses on hydrocarbons exploration, production, refining, distribution, and shipping, as well as provides crude oil marketing services. Saudi Aramco serves customers worldwide.

<ul><li>VASRO has published an update report on Saudi Aramco Base Oil Company – Luberef following the company’s Q1 2026 results.</li><li>The core investment message is unchanged: Luberef remains a focused base-oils platform with a strong balance sheet, visible execution milestones, and a defined path toward product-mix improvement as Growth II moves closer to completion.</li><li>Q1 2026 was not a normalized run-rate quarter. It was an execution checkpoint — and the checkpoint was constructive.</li></ul>

VASRO has published an update report on Saudi Aramco Base Oil Company – Luberef following the company’s Q1 2026 results.The core investment message is unchanged: Luberef remains a focused base-oils platform with a strong balance sheet, visible execution milestones, and a defined path toward product-mix improvement as Growth II moves closer to completion.Q1 2026 was not a normalized run-rate quarter. It was an execution checkpoint — and the checkpoint was constructive.

Saudi Aramco Base Oil Company – Q1 Confirms Earnings Resilience and Growth II Progress

Saudi Aramco Base Oil Company – Luberef: Q1 Confirms Earnings Resilience and Growth II Progress

Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its smelltech platform, powered by AI Nose and smell language model (SLM), digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Active clinical programs include HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis (FCGS). Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age.

<ul><li>The report, titled“AI Nose Builds a Broader Operating Footprint Across Semiconductors and Healthcare,”reviews Ainos’ Q1 2026 progress and frames the quarter as a build-out phase for the company’s AI Nose platform.</li><li>Ainos’ update points to a broader operating footprint across four verticals: backend semiconductor manufacturing, front-end wafer-fab manufacturing, robotics integration, and healthcare infrastructure. The company continues to advance its previously disclosed semiconductor deployment programs, while also expanding AI Nose into hospital infrastructure environments through the April partnership with MacKay Memorial Hospital and Topco.</li><li>From VASRO’s perspective, the key investment-relevant point is not yet near-term revenue scale, but the widening deployment map. Q1 2026 revenue remained minimal at USD 161, while the company reported operating costs of USD 2.28 million, a net loss of USD 2.46 million, and cash on hand of USD 2.84 million. The quarter therefore remains best understood as a commercialization-build period rather than a revenue-ramp quarter.</li></ul>

The report, titled“AI Nose Builds a Broader Operating Footprint Across Semiconductors and Healthcare,”reviews Ainos’ Q1 2026 progress and frames the quarter as a build-out phase for the company’s AI Nose platform.Ainos’ update points to a broader operating footprint across four verticals: backend semiconductor manufacturing, front-end wafer-fab manufacturing, robotics integration, and healthcare infrastructure. The company continues to advance its previously disclosed semiconductor deployment programs, while also expanding AI Nose into hospital infrastructure environments through the April partnership with MacKay Memorial Hospital and Topco.From VASRO’s perspective, the key investment-relevant point is not yet near-term revenue scale, but the widening deployment map. Q1 2026 revenue remained minimal at USD 161, while the company reported operating costs of USD 2.28 million, a net loss of USD 2.46 million, and cash on hand of USD 2.84 million. The quarter therefore remains best understood as a commercialization-build period rather than a revenue-ramp quarter.

Ainos, Inc.: AI Nose Builds Broader Operating Footprint Across Semiconductors and Healthcare

Spinneys 1961 Holding PLC operates as a holding company. The Company, through its subsidiaries, is an operator of online grocery retail supermarkets that deliver fruits and vegetables, bakery, diary, deli and chilled foods, seafood, beverages, as well as household, flowers, cosmetics, and other related products. Spinneys 1961 Holding serves customers in the United Arab Emirates.

<ul><li>VASRO has published an update report onSpinneys 1961 Holding PLCfollowing the company’s Q1 2026 results. The core investment message is unchanged: demand quality remains strong, the operating platform proved resilient under stress, and the balance sheet continues to support self-funded expansion.</li><li>Spinneys reportedQ1 2026 revenue of AED 1,014m, up11.9% year-on-year, supported by7.4% like-for-like growth. This was the second-strongest quarterly LFL performance in the past four quarters and confirms that the underlying consumer trend remains intact. Transaction growth was also solid, with10.8m transactions, up8.5%, while average basket size increased3.4%toAED 92.9. Online participation reached18.8%, with ecommerce revenue growing34.9%year-on-year.</li><li>The reported margin pressure needs context. Gross margin declined by120 basis pointsto40.1%, and adjusted EBITDA margin fell by190 basis pointsto18.2%. However, VASRO views this primarily as a March-specific logistics event rather than a structural reset. During March, regional disruption meant that only20% of planned shipmentswere received, while remaining shipments faced an average delay of21 days. This led to higher freight costs, non-standard routing, increased use of air freight, higher wastage, and inventory provisions.</li></ul>

VASRO has published an update report onSpinneys 1961 Holding PLCfollowing the company’s Q1 2026 results. The core investment message is unchanged: demand quality remains strong, the operating platform proved resilient under stress, and the balance sheet continues to support self-funded expansion.Spinneys reportedQ1 2026 revenue of AED 1,014m, up11.9% year-on-year, supported by7.4% like-for-like growth. This was the second-strongest quarterly LFL performance in the past four quarters and confirms that the underlying consumer trend remains intact. Transaction growth was also solid, with10.8m transactions, up8.5%, while average basket size increased3.4%toAED 92.9. Online participation reached18.8%, with ecommerce revenue growing34.9%year-on-year.The reported margin pressure needs context. Gross margin declined by120 basis pointsto40.1%, and adjusted EBITDA margin fell by190 basis pointsto18.2%. However, VASRO views this primarily as a March-specific logistics event rather than a structural reset. During March, regional disruption meant that only20% of planned shipmentswere received, while remaining shipments faced an average delay of21 days. This led to higher freight costs, non-standard routing, increased use of air freight, higher wastage, and inventory provisions.

Spinneys 1961 Holding PLC: Demand Quality Holds Despite March Logistics Shock – VASRO Reiterates BUY

<ul>
<li>tracked. This update does not introduce a new thesis; it gives the existing one more structure. FY2025 revenue rose to USD 124,157, gross profit turned positive at USD 102,911, gross margin reached 82.9%, and the filed 10-K shows that 99.4% of FY2025 revenue came from AI Nose-related programs. That matters because the near-term commercial story is now being carried much more clearly by industrial smelltech, not by broad platform optionality alone.</li>
<li>The more important change is on execution visibility. Management now points to around 200 front-end wafer-fab systems targeted for technical validation, around 1,400 systems under the previously disclosed three-year USD 2.1 million ASE framework, a disclosed ~USD 350k deposit, and a stated Q2 2026 completion target for that rollout phase. The 10-K also adds a contracted minimum commitment of 600 AI Nose units with a semiconductor engineering and systems-integration partner, while ~USD 2.82 million of financing from an ASE group company strengthens liquidity.</li>
<li>The correct investor read remains disciplined: Ainos is moving from proof-of-concept toward early commercial execution, but broader scale-up still depends on validation results and contractual conversion. What has improved is not certainty of full rollout, but the number of visible checkpoints the market can now track.</li>
</ul>


tracked. This update does not introduce a new thesis; it gives the existing one more structure. FY2025 revenue rose to USD 124,157, gross profit turned positive at USD 102,911, gross margin reached 82.9%, and the filed 10-K shows that 99.4% of FY2025 revenue came from AI Nose-related programs. That matters because the near-term commercial story is now being carried much more clearly by industrial smelltech, not by broad platform optionality alone.
The more important change is on execution visibility. Management now points to around 200 front-end wafer-fab systems targeted for technical validation, around 1,400 systems under the previously disclosed three-year USD 2.1 million ASE framework, a disclosed ~USD 350k deposit, and a stated Q2 2026 completion target for that rollout phase. The 10-K also adds a contracted minimum commitment of 600 AI Nose units with a semiconductor engineering and systems-integration partner, while ~USD 2.82 million of financing from an ASE group company strengthens liquidity.
The correct investor read remains disciplined: Ainos is moving from proof-of-concept toward early commercial execution, but broader scale-up still depends on validation results and contractual conversion. What has improved is not certainty of full rollout, but the number of visible checkpoints the market can now track.


Ainos Update — FY2025 and the 10-K Add Structure to 2026 AI Nose Execution